Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANKRD20A9P is a pseudogene, meaning it is a non-functional sequence in the genome that resembles a protein-coding gene but does not produce a functional protein[3][4][8]. Pseudogenes generally arise from duplication or retrotransposition events that introduce mutations or other disruptions, rendering them non-coding[5][6]. While some pseudogenes can regulate gene expression at the RNA level, for example by acting as decoys for microRNAs (competing endogenous RNAs) or precursors for small interfering RNAs, there is no evidence for such a function specifically attributed to ANKRD20A9P[5][6]. There are no known drug interactions, disease associations, or biomarker roles for this pseudogene. Gene databases and genomic resources list it as a well-annotated pseudogene without known protein-coding capacity or direct therapeutic relevance[3][4][8].
None reported; as a pseudogene, there is no canonical mechanism of action
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain 20 family member A9, pseudogene (ANKRD20A9P).